NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $1.82 +0.03 (+1.68%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.76 -0.06 (-3.24%) As of 04/25/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Skye Bioscience Stock (NASDAQ:SKYE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Skye Bioscience alerts:Sign Up Key Stats Today's Range$1.75▼$1.9250-Day Range$1.20▼$2.3052-Week Range$1.14▼$13.51Volume415,800 shsAverage Volume349,652 shsMarket Capitalization$56.37 millionP/E RatioN/ADividend YieldN/APrice Target$16.60Consensus RatingBuy Company OverviewSkye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More… Skye Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreSKYE MarketRank™: Skye Bioscience scored higher than 20% of companies evaluated by MarketBeat, and ranked 772nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($1.04) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Skye Bioscience is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Skye Bioscience is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.71% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Skye Bioscience has recently increased by 10.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.71% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Skye Bioscience has recently increased by 10.68%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.98 News SentimentSkye Bioscience has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Skye Bioscience this week, compared to 3 articles on an average week.Search Interest4 people have searched for SKYE on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address SKYE Stock News HeadlinesSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 25 at 8:06 PM | globenewswire.comWilliam Blair Comments on Skye Bioscience Q1 EarningsApril 19, 2025 | americanbankingnews.com2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years. April 26, 2025 | Stansberry Research (Ad)Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) Price Target at $16.60April 19, 2025 | americanbankingnews.comAnalysts Offer Predictions for Skye Bioscience Q2 EarningsApril 18, 2025 | americanbankingnews.comA Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash ValueApril 16, 2025 | seekingalpha.comSkye Bioscience announces new preclinical data for nimacimabApril 15, 2025 | markets.businessinsider.comSkye Bioscience Stock Rises on Preclinical Data for Weight Loss DrugApril 15, 2025 | marketwatch.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $2.83 at the start of the year. Since then, SKYE stock has decreased by 35.7% and is now trading at $1.82. View the best growth stocks for 2025 here. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) released its quarterly earnings data on Thursday, March, 20th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.06. Read the conference call transcript. Who are Skye Bioscience's major shareholders? Top institutional investors of Skye Bioscience include Capital Advisors Wealth Management LLC (0.07%). Insiders that own company stock include Punit Dhillon, Paul A Grayson, Kaitlyn Arsenault, Tuan Tu Diep and Andrew J Schwab. View institutional ownership trends. How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Skye Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG). Company Calendar Last Earnings3/20/2025Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SKYE Previous SymbolNASDAQ:SKYE CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$16.60 High Stock Price Target$20.00 Low Stock Price Target$14.00 Potential Upside/Downside+812.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.78% Return on Assets-37.44% Debt Debt-to-Equity RatioN/A Current Ratio14.19 Quick Ratio14.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-10.71Miscellaneous Outstanding Shares30,975,000Free Float29,428,000Market Cap$56.37 million OptionableOptionable Beta1.88 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:SKYE) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.